Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies

British Journal of Cancer

Volumn 104, Issue 3, 2011, Pages 399-406

  Gore, M E ^a   Larkin, J M G ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

chronic disease; combinatorial therapy; renal cell carcinoma; sequential therapy; sunitinib malate; targeted agents

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CEDIRANIB; EVEROLIMUS; LINIFANIB; PAZOPANIB; PLACEBO; REYORAFENIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG TARGETING; DYSGEUSIA; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIVER TOXICITY; MOUTH ULCER; NAUSEA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; REVIEW; SKIN DISCOLORATION; STOMATITIS; THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CHRONIC DISEASE; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 79551597099     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6606084     Document Type: Review

References (59)

1. Antonelli A, Cozzoli A, Zani D, Zanotelli T, Nicolai M, Cunico SC, Simeone C (2007) The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 99: 296-300
2. Biswas S, Troy H, Leek R, Chung Y-L, Li J, Raval RR, Turley H, Gatter K, Pezzella F, Griffiths JR, Stubbs M, Harris AL (2010) Effects of HIF-1a and HIF2a on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. J Oncol 2010: 757908
3. Bhargava P, Esteves B, Nosov DA, Lipatov ON, Anishchenko AA, Chacko RT (2009) Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol 27: (Abstract 5032)
4. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53: 917-930
5. Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T (2004) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (3): CD001425
6. Dutcher JP, Wild D, Hudes GR, Stadler WM, Kim S, Tarazi JC, Rosbrook B, Rini BI (2008) Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. Poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, 30 May- 3 June, 2008 (Abstract 5127)
7. Eisen T, Joensuu H, Nathan P, Harper P, Wojtukiewicz M, Nicholson S, Bahl A, Tomczak P, Wagner A, Quinn D (2009) Phase II trial of the oral multikinase inhibitor BAY 73-4506 as 1st-line therapy in patients with metastatic or unresectable renal cell carcinoma (RCC). Eur J Cancer Supplements 7, Abstract 7.105; oral
8. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010a) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28: 2144-2150
9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009a) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318
10. Escudier B, Kataja V (2010b) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v137-v139
11. Escudier B, Ravaud A, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson J, Figlin RA, Motzer RJ (2008) Phase-3 randomised trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Ann Oncol 19(Suppl. 8): viii45 (Abstract 72O)
12. Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM (2009b) Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1280-1289
13. Eskens F, de Jonge M, Esteves B, Cotreau M, Bhargava P, Ryan J, van Doorn L, Isoe T, Hayashi K, Ekman L, Burger H, Verweij J (2008) Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1, -2 and -3 tyrosine kinase inhibitor, in patients with advanced solid tumors. Annual Meeting of the American Association for Cancer Research, April 2008: abstract LB-201
14. Feldman DR, Kondagunta GV, Ronnen EA, Fischer P, Chang R, Baum M, Ginsberg MS, Ishill N, Patil S, Motzer RJ (2007) Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement): (Abstract 5099)
15. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592
16. Fisher RI, Rosenberg SA, Fyfe G (2000) Long-term survival update for highdose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6(Suppl 1): S55-S57
17. Hainsworth JD, Spigel DR, Burris III HA, Waterhouse D, Clark BL, Whorf R (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28: 2131-2136
18. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/ pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66: 357-371
19. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian C-N, Kahnoski R, Futreal PA, Furge KA, Teh BT (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70: 1063-1071
20. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, OToole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281
21. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353: 172-187
22. Le Tourneau C, Faivre S, Serova M, Raymond E (2008) mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 99(8): 1197-1203
23. McDermott DF, Ghebremichael MS, Signoretti S, Margolin KA, Clark J, Sosman JA, Dutcher JP, Logan T, Figlin RA, Atkins MB, on behalf of the Cytokine Working Group (2010) The high-dose aldesleukin (HD IL-2) SELECT trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 28(15s) (Abstract 4514)
24. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133-141
25. Medina MA, Munoz-Chapuli R, Quesada AR (2007) Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope. J Cell Mol Med 11: 374-382
26. Merchan JR, Lui G, Fitch T, Picus J, Qin R, Pitot HC, Maples W, Erlichman C (2007) Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol 2007: 25. ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement): (Abstract 5034)
27. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335: 865-875
28. Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24: 5601-5608
29. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 372: 449-456
30. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116: 4256-4265
31. Motzer RJ, Hutson TE, Tomczak P, Dror Michaelson M, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590
32. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124
33. Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, Protheroe A, Mookerjee B, Pike L, Gore ME (2009) Final results of a phase II randomised study of cediranib (RECENTINt) in patients with advanced renal cell carcinoma (RCC). Eur J Cancer Supplements 7: 21
34. Oudard S, Beuselinck B, Decoene J, Albers P (2010) Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat Rev; e-pub ahead of print
35. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108
36. Patel PH, Senico PL, Curiel RE, Motzer RJ (2009) Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 7: 24-27
37. Rini BI, Flaherty K (2008) Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol 26: 543-549
38. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dowlati A, Dreicer R (2009a) A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 15: 6277-6283
39. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Ivy P, Chen HX, Dowlati A, Dreicer R (2010c) Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol 28(17): e284-e285
40. Rini BI, Halabi S, Rosenberg J, Stadler WM, Vaena DA, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2009b) Bevacizumab plus interferonalpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. J Clin Oncol 27. Abstr LBA5019 - Oral presentation
41. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2010b) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28: 137-143
42. Rini BI, Hutson TE, Elson P, Heng DY, Knox JJ, Michaelson D, Choueiri TK, Escudier BJ (2010a) Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma. American Society for Clinical Oncology - Genitourinary Cancers Symposium. Abstr 319 - Oral presentation
43. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26: 3743-3748
44. Rini BI, Wilding G, Hudes G, Stadler W, Kim SJ (2007) Axitinib (AG-013736) in patients with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol 25: 242S
45. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8: 975-984
46. Ryan CW, Goldman BH, Lara Jr PN, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan CX, Drabkin HA, Crawford ED (2007) Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25: 3296-3301
47. Sablin M, Bouaita L, Balleyguier C, Gautier J (2007) Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients. J Clin Oncol. ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement):(Abstract 5038)
48. Schmidinger M, Bellmunt J (2010) Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 36(5): 416-424
49. Schmidt C (2008) Resistance revisited: looking back at 10 years of multidrug resistance research. J Natl Cancer Inst 100: 1428-1429
50. Sessa C, Guibal A, Del CG, Ruegg C (2008) Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 5: 378-391
51. Sosman JA, Flaherty K, Atkins MB (2006) A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J Clin Oncol 24(Suppl. 18S): 128s
52. Sosman JA, Flaherty KT, Atkins MB, McDermott DF, Rothenberg ML, Vermeulen WL, Harlacker K, Hsu A, Wright JJ, Puzanof I (2008) Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). Poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, 30 May-3 June 2008 (Abstract 5011)
53. Sosman JA, Puzanov I, Atkins MB (2007) Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res 13: 764s-769s
54. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010a) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068
55. Sternberg CN, Hawkins R, Szczylik C, Davis ID, Wagstaff J, McCann L, Chen M, Rubin SD (2010b) Randomized, double-blind phase III study of pazopanib in patients with advanced metastatic renal cell carcinoma (mRCC): final overall survival (OS) results. Ann Oncol 21(Suppl. 8): viii10 Abstract LBA22
56. Tamaskar I, Shaheen P, Wood L (2006) Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. J Clin Oncol 24: 4597
57. Tannir N, Wong Y, Kollmannsberger C, Ernstoff MS, Perry DJ, Appleman LJ, Posadas E, Qian J, Ricker JL, Michaelson MD (2009) Phase 2 results of ABT-869 treatment in patients with advanced renal cell cancer (RCC) after sunitinib failure. Eur J Cancer Supplements 7: 425
58. Toschi A, Lee E, Gadir N, Ohh M, Foster DA (2008) Differential dependence of hypoxia-inducible factors 1a and 2a on mTORC1 and mTORC2. J Biol Chem 283: 34495-34499
59. Whorf RC, Hainsworth JD, Spigel DR, Yardley DA, Burris III HA, Waterhouse DM, Vazquez ER, Greco FA (2008) Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). Poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, 30 May-3 June 2008. http://www.clinicaltrials.gov (2010) http://clinicaltrials.gov/